|
Synonyms: AZP-3601 | AZP3601 | LA-PTH [2]
Compound class:
Peptide
Comment: Eneboparatide (AZP-3601) is a synthetic long-acting PTH receptor 1 agonist [1-2]. It is a fusion of modified PTH(1-14) with amino acid substitutions and PTHrP(15-36). Compared to native human PTH, amino acid substitution in the PTH region of eneboparatide are S3>A, H5>I, L8>M, D10>Q, K11>R, G12>A, S14>W,L18>A, F22>A, H26>K Eneboparatide associates more potently with the R0 conformation of PTH1R (in the presence of 125I-PTH(1-34) and GTPγS to block receptor-G protein-coupling, compared to PTH(1-34) or PTH(1-84) [2]. All three peptides interact with the RG (G protein-coupled) conformation of PTH1R with similar potencies.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| No information available. |
Summary of Clinical Use  |
| AstraZeneca are investigating eneboparatide as a treatment for chronic hypoparathyroidism [3], as an alternative to conventional therapy (active vitamin D and oral calcium supplementation). |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT05239221 | AZP-3601 SAD and MAD Study in Healthy Subjects and Patients With Hypoparathyroidism | Phase 1/Phase 2 Interventional | Amolyt Pharma | ||
| NCT05778071 | Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism | Phase 3 Interventional | Amolyt Pharma | 3 | |
